Literature DB >> 3339106

Adenosine receptors and the nucleoside transporter in human brain vasculature.

R N Kalaria1, S I Harik.   

Abstract

Evidence suggests that adenosine modulates neuronal and cerebral vascular functions by interacting with specific receptors on brain cells and blood vessels. Adenosine and other nucleosides are also transported across the blood-brain barrier via a saturable, carrier-mediated mechanism. Using direct ligand binding methods, we studied the two adenosine receptor subtypes, A1 and A2 and the nucleoside transporter moiety in human brain microvessels, pial vessels, choroid plexus, and cerebral cortex membranes. The following specific tritiated ligands were used: cyclohexyladenosine (CHA) for A1 receptors; 5'-N-ethylcarboxamide adenosine (NECA) for A2 receptors; nitrobenzylthioinosine (NBMPR) and dipyridamole (DPY) for nucleoside transporters. We find that cerebral microvessels, pial vessels, and choroid plexus have few, if any, A1 receptors, in contradistinction to cerebral membranes, which have a 10-20-fold higher density of A1 receptor sites. Specific high-affinity NECA binding to A2 receptors in cerebral microvessels, pial vessels, and choroid plexus was saturable and was equivalent to that of cerebral cortical membranes. The Bmax and Kd of the high-affinity NECA binding to vessel preparations were approximately 1.3 pmol/mg protein and approximately 250 nM, respectively, which is similar to our previous findings in the rat and pig. NBMPR and DPY binding were also saturable and were consistent with a single class of high-affinity binding sites. The density of nucleoside transporters was approximately four-fold higher in cerebral microvessels than in cerebral cortex, pial vessels, and choroid plexus. These results suggest that human cerebral microvessels have A2, but not A1, receptors and are particularly enriched with the adenosine transporter moiety.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3339106     DOI: 10.1038/jcbfm.1988.5

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  8 in total

Review 1.  Ventilatory and cerebrovascular regulation and integration at high-altitude.

Authors:  Ryan L Hoiland; Connor A Howe; Geoff B Coombs; Philip N Ainslie
Journal:  Clin Auton Res       Date:  2018-03-24       Impact factor: 4.435

2.  Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia.

Authors:  P Andiné; K A Rudolphi; B B Fredholm; H Hagberg
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

3.  Identification of a stable fragment of the Alzheimer amyloid precursor containing the beta-protein in brain microvessels.

Authors:  A Tamaoka; R N Kalaria; I Lieberburg; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

4.  Contribution of P1-(A2b subtype) and P2-purinoceptors to the control of vascular tone in the rat isolated mesenteric arterial bed.

Authors:  A Rubino; V Ralevic; G Burnstock
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

Review 5.  Hypoxemia, oxygen content, and the regulation of cerebral blood flow.

Authors:  Ryan L Hoiland; Anthony R Bain; Mathew G Rieger; Damian M Bailey; Philip N Ainslie
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-12-16       Impact factor: 3.619

Review 6.  Guanosine and its role in neuropathologies.

Authors:  Luis E B Bettio; Joana Gil-Mohapel; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2016-03-22       Impact factor: 3.765

Review 7.  Purines: From Diagnostic Biomarkers to Therapeutic Agents in Brain Injury.

Authors:  Bruno G Frenguelli; Nicholas Dale
Journal:  Neurosci Bull       Date:  2020-06-15       Impact factor: 5.203

Review 8.  Purinergic Regulation of Endothelial Barrier Function.

Authors:  Muhammad Aslam; Dursun Gündüz; Christian Troidl; Jacqueline Heger; Christian W Hamm; Rainer Schulz
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.